Acceleration of HIV dementia with methamphetamine and cocaine
We report a patient with rapidly accelerating HIV dementia accompanied by seizures and an unusual movement disorder despite highly potent antiretroviral therapy. This clinical constellation was associated with the non-parenteral use of methamphetamine and cocaine. Fractional enhancement time on post contrast magnetic resonance imaging studies revealed a progressive breakdown of the blood brain barrier particularly in the basal ganglia. The movement disorder but not the dementia responded to a combination of dopamine replacement and anticholinergic therapy. While the movement disorder may have been unmasked by concomitant anticonvulsant therapy, we suggestin this instance, that prior drug abuse synergized with HIV to cause a domino effect on cerebral function. Careful attention and analysis to histories of remote non-injecting drug abuse may help substantiate our hypothesis.
KeywordsHIV brain AIDS cocaine methamphetamine
Unable to display preview. Download preview PDF.
- Aweeka F, Jayewardene A, Staprans S, Bellibas SE, Kearney B, Lizak P, Novakovic-Agopian T, Price RW (1999). Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol 20: 39–43.PubMedGoogle Scholar
- Concha M, Graham NM, Munoz A, Vlahov D, Royal WD, Updike M, Nance-Sproson T, Scines OA, McArthur JC (1992). Effect of chronic substance abuse on the neuropyschological performance of intravenous drug users with a high prevalence of HIV-l seropositivity. Am J Epidemiol 136: 1338–1348.PubMedGoogle Scholar
- Nath A, Jones M, W, M, Booze RM, Mactutus C, Bell J, Mattson M (2000). Neurotoxicity and E)ysfunction of Eopaminergic Systems Associated with AIDS Dementia. J Psychopharmacology (in press).Google Scholar
- Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A, Henry K (1999). Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS 13: 1677–1685.CrossRefPubMedGoogle Scholar
- Sacktor NC, Lyles RH, Skolasky RL, Anderson DE, McArthur JC, McFarlane G, Scines OA, Becker JT, Cohen B, Wesch J, Miller EN (1999). Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology 52: 1640–1647.PubMedGoogle Scholar
- Scines OA, Galai N, McArthur JC, Cohn S, Royal W, 3rd, Esposito D, Vlahov D (1997). HIV infection and cognition in intravenous drug users: long-term follow-up. Neurology 48: 223–230.Google Scholar
- Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB, Ravert HT, Musachio J, McCann UD, Ricaurte GA (1998). Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18: 419–427.PubMedGoogle Scholar
- Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson WR, Shannak K, Deck J, Niznik HB, Kish SJ (1996b). Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 40: 428–439.CrossRefPubMedGoogle Scholar